More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

We are a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases through cell therapy. Cell therapy is a process of using a patient’s own cells to better ...

At Insmed, every moment and every patient counts — and so does every person who joins in. As a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare ...

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity ...